In:
Digestive Surgery, S. Karger AG, Vol. 25, No. 1 ( 2008), p. 52-59
Abstract:
〈 i 〉 Aim: 〈 /i 〉 The purpose of this study was to evaluate the safety and efficacy of percutaneous transhepatic portal vein embolization of the right portal vein with an Ethibloc/Lipiodol mixture to induce hypertrophy of the left liver lobe in patients with primarily unresectable liver tumor. 〈 i 〉 Methods: 〈 /i 〉 15 patients (8 primary liver tumors, 7 liver metastases) underwent portal vein embolization. Liver volumetry, duration of hospitalization, complication rates, relevant laboratory values were documented. 〈 i 〉 Results: 〈 /i 〉 In 13/15 patients (84.6%) embolization could be performed with a median of 8.8 ml (range 1.5–28 ml) Ethibloc/Lipiodol. One minor procedure-related complication (subcapsular hematoma) occurred, which did not affect the two-step liver resection. No patient developed acute liver failure after embolization or liver resection. The volume of the left liver lobe increased significantly (p = 0.0015) by 25% from a median of 750 ml (587–1,114 ml) to 967 ml (597–1,249 ml). 11/13 (81.8%) of the embolized patients underwent liver resection at a median of 49 days after embolization. Median hospitalization time was 4 days after embolization and 7 days after liver resection. Median overall survival of the 11 operated patients was 376 days. 〈 i 〉 Conclusion: 〈 /i 〉 Percutaneous transhepatic portal vein embolization using an Ethibloc/Lipiodol mixture is a safe, feasible, and efficient interventional procedure.
Type of Medium:
Online Resource
ISSN:
0253-4886
,
1421-9883
Language:
English
Publisher:
S. Karger AG
Publication Date:
2008
detail.hit.zdb_id:
1468560-7
Bookmarklink